Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis

References

• Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005; 206: 296–305
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521–33
   PubMed Web of Science ®Google Scholar
• Melmed GY, Abreu MT. New insights into the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep 2004; 6: 474–81
   PubMedGoogle Scholar
• Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002; 252: 475–96
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495–49
   PubMed Web of Science ®Google Scholar
• Dionne S, Hiscott J, D'Agata I. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997; 42: 1557–66
   PubMed Web of Science ®Google Scholar
• McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001; 50: 491–5
   PubMed Web of Science ®Google Scholar
• Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004; 19: 308–15
   PubMedGoogle Scholar
• Woywodt A, Ludwig D, Neustock P, Kruse A, Schwarting K, Jantschek G, et al. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 267–76
   PubMed Web of Science ®Google Scholar
• Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 66–74
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Neurath M, Boirivant M, Klein JS, de la MC, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261–70
   PubMed Web of Science ®Google Scholar
• Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 233–6
   PubMed Web of Science ®Google Scholar
• Inoue S, Matsumoto T, Iida M, Mizuno M, Kuroki F, Hoshika K, et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 1999; 94: 2441–6
   PubMed Web of Science ®Google Scholar
• Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46: 111–23
   PubMedGoogle Scholar
• Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K, Okita K. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol 2002; 37: 345–53
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913–7
   PubMed Web of Science ®Google Scholar
• Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297–301
   PubMed Web of Science ®Google Scholar
• Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T, Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med 2003; 11: 175–9
   PubMed Web of Science ®Google Scholar
• Matsuzaki K, Hokari R, Kato S, Tsuzuki Y, Tanaka H, Kurihara C, et al. Differential expression of CCR5 and CRTH2 on infiltrated cells in colonic mucosa of patients with ulcerative colitis. J Gastroenterol Hepatol 2003; 18: 1081–8
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002; 97: 2820–8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made?. Gut 2004; 53: 1366–73
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer L, Schreiber S, Colombel J, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005; 5: 10–8
   PubMedGoogle Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805–11
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76
   PubMed Web of Science ®Google Scholar
• Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518–32
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894–8
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Frenz MB, Dunckley P, Camporota L, Jewell DP, Travis SP. Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol 2005; 100: 1117–20
   PubMed Web of Science ®Google Scholar
• Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006; 66: 249–59
   PubMed Web of Science ®Google Scholar
• Goll R, Olsen T, Cui G, Florholmen J. Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR. BMC Bioinformatics 2006; 7: 107
   PubMed Web of Science ®Google Scholar
• Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, , et al Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 2006
   Web of Science ®Google Scholar
• Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443–8
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390–407
   PubMedGoogle Scholar
• Brandtzaeg P. Autoimmunity and ulcerative colitis: can two enigmas make sense together?. Gastroenterology 1995; 109: 307–12
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Carlsen HS, Halstensen TS. The B-cell system in inflammatory bowel disease. Adv Exp Med Biol 2006; 579: 149–67
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148–57
   PubMed Web of Science ®Google Scholar
• Bruin KF, Hommes DW, Jansen J, Tytgat GN, Wouter ten CJ, Van Deventer SJ. Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 791–5
   PubMed Web of Science ®Google Scholar
• Zimmerman MJ, Jewell DP. Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 1996; 10(Suppl 2)93–8
   PubMed Web of Science ®Google Scholar
• Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550–64
   PubMed Web of Science ®Google Scholar
• Kakazu T, Hara J, Matsumoto T, Nakamura S, Oshitani N, Arakawa T, et al. Type 1 T-helper cell predominance in granulomas of Crohn's disease. Am J Gastroenterol 1999; 94: 2149–55
   PubMed Web of Science ®Google Scholar
• Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these co-stimulatory molecules in human gut lamina propria. Inflamm Bowel Dis 2006; 12: 1013–24
   PubMed Web of Science ®Google Scholar
• Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol 2003; 4: 503–5
   PubMed Web of Science ®Google Scholar
• Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 2006; 22: 361–4
   PubMed Web of Science ®Google Scholar
• Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005; 206: 260–76
   PubMed Web of Science ®Google Scholar